3-Methylsulfonyloxybutyl acetate | 912816-36-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 3-Methylsulfonyloxybutyl acetate
• 英文别名: 3-methylsulfonyloxybutyl acetate
• CAS: 912816-36-5
• 化学式: C₇H₁₄O₅S
• 分子量: 210.251
• InChiKey: KMMYBXMEIPCITC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-Methylsulfonyloxybutyl acetate 、 5-乙基-2-羟基-二苯甲酮 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 acetic acid 3-(2-benzoyl-4-ethyl-phenoxy)-butyl ester
  参考文献：
  名称：

  Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile

  摘要：

  The design and synthesis of the dual peroxisome proliferator-activated receptor ( PPAR) gamma/delta agonist (R)-3-{4-[3-(4-chloro-2-phenoxyphenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid (20) for the treatment of type 2 diabetes and associated dyslipidemia is described. The compound possesses a potent dual hPPAR gamma/delta agonist profile (IC50 = 19 nM/4 nM; EC50 = 102 nM/6 nM for hPPAR gamma and hPPAR delta, respectively). In preclinical models, the compound improves insulin sensitivity and reverses diabetic hyperglycemia with less weight gain at a given level of glucose control relative to rosiglitazone.

  DOI：

  10.1021/jm060617c
• 作为产物：
  描述：

  3-羟基丁基乙酸酯 、 甲基磺酰氯 在 三乙胺 作用下， 生成 3-Methylsulfonyloxybutyl acetate
  参考文献：
  名称：

  Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile

  摘要：

  The design and synthesis of the dual peroxisome proliferator-activated receptor ( PPAR) gamma/delta agonist (R)-3-{4-[3-(4-chloro-2-phenoxyphenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid (20) for the treatment of type 2 diabetes and associated dyslipidemia is described. The compound possesses a potent dual hPPAR gamma/delta agonist profile (IC50 = 19 nM/4 nM; EC50 = 102 nM/6 nM for hPPAR gamma and hPPAR delta, respectively). In preclinical models, the compound improves insulin sensitivity and reverses diabetic hyperglycemia with less weight gain at a given level of glucose control relative to rosiglitazone.

  DOI：

  10.1021/jm060617c

文献信息

• NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM BATTERY, LITHIUM BATTERY USING SAME, AND FORMYLOXY GROUP-CONTAINING COMPOUND USED THEREIN
  申请人：Abe Koji

  公开号：US20110183199A1

  公开（公告）日：2011-07-28

  Disclosed are a nonaqueous electrolytic solution for lithium secondary battery comprising an electrolyte dissolved in a nonaqueous solvent and containing at least one compound represented by the formula (I) in an amount of from 0.01 to 10% by mass of the nonaqueous electrolytic solution; a lithium battery containing the electrolytic solution and excellent in low-temperature and high-temperature cycle property; and a formyloxy group-containing compound having a specific structure which is used in lithium batteries, etc. (wherein X represents an alkylene group, an alkenylene group or an alkynylene group; R 1 represents H, an alkyl group, a cycloalkyl group or a group of the formula (II); R 2 represents an alkyl group, a cycloalkyl group or a group of the formula (II); R 3 to R 7 each represent H, F, a methoxy group or an ethoxy group.)

  本发明揭示了一种用于锂二次电池的非水电解质溶液，其中包含在非水溶剂中溶解的电解质，并且含有至少一种化合物，该化合物由公式（I）表示，并占非水电解质溶液的质量的0.01％至10％; 一种锂电池，其中包含该电解质溶液，并具有低温和高温循环性能优异的特点;以及一种具有特定结构的甲氧基羰基基团的化合物，该化合物用于锂电池等中。（其中X代表烷基，烯基或炔基；R1代表H，烷基，环烷基或公式（II）的基团；R2代表烷基，环烷基或公式（II）的基团；R3至R7每个代表H，F，甲氧基或乙氧基。）
• US8383274B2
  申请人：——

  公开号：US8383274B2

  公开（公告）日：2013-02-26
• Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile
  作者：Yanping Xu、Garret J. Etgen、Carol L. Broderick、Emily Canada、Isabel Gonzalez、Jason Lamar、Chahrzad Montrose-Rafizadeh、Brian A. Oldham、John J. Osborne、Chaoyu Xie、Qing Shi、Leonard L. Winneroski、Jeremy York、Nathan Yumibe、Richard Zink、Nathan Mantlo

  DOI：10.1021/jm060617c

  日期：2006.9.1

  The design and synthesis of the dual peroxisome proliferator-activated receptor ( PPAR) gamma/delta agonist (R)-3-4-[3-(4-chloro-2-phenoxyphenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid (20) for the treatment of type 2 diabetes and associated dyslipidemia is described. The compound possesses a potent dual hPPAR gamma/delta agonist profile (IC50 = 19 nM/4 nM; EC50 = 102 nM/6 nM for hPPAR gamma and hPPAR delta, respectively). In preclinical models, the compound improves insulin sensitivity and reverses diabetic hyperglycemia with less weight gain at a given level of glucose control relative to rosiglitazone.